References

ometendo

Ожирение и метаболизм

Obesity and metabolism

2071-87132306-5524

Endocrinology Research Centre

10.14341/2071-8713-5189

ometendo-5189

Research Article

Статьи

Articles

Адипоцитокины в научной и клинической практике

Adipotsitokiny v nauchnoy i klinicheskoy praktike

Kosygina

A V

annakosygina@gmail.com

2011

15032011

№1 (2011)

3239

2011

Kosygina A.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.omet-endojournals.ru/jour/article/view/5189

В последние десятилетия избыточная масса тела и ожирение стали одной из важнейших проблем для жителей боль- шинства стран мира. По данным Всемирной организации здравоохранения (ВОЗ), более миллиарда человек на планете имеют лишний вес, зарегистрировано более 300 млн больных ожирением. Данные клинических и экспериментальных исследований показывают отчетливую взаимосвязь между ожирением и рядом хронических заболеваний, таких как сахарный диабет 2 типа (СД2), атеросклероз, ИБС, высоким риском развития онкологической патологии, нарушениями в репродуктивной сфере, патологией опорно-двигательного аппарата, а также отклонениями в психическом статусе и процессах социальной адапта- ции. Поэтому значительные усилия современной эндокринологии направлены на изучение этиопатогенетических аспектов, лежащих в основе этих заболеваний и идентификацию возможных маркеров.

In recent decades, overweight and obesity have become a major problem for most countries. According to the World Health Organization (WHO), more than a billion people worldwide are overweight and more than 300 million are obese. These clinical and experimental studies highlight a clear relationship between obesity and several chronic diseases such as type 2 diabetes mellitus (T2DM), atherosclerosis, coronary heart disease, high risk of oncological diseases, disorders of the reproductive sphere, pathology of the musculoskeletal system, as well as deviations in mental status and processes of social adaptation. Therefore, considerable efforts of modern endocrinology focused on the study of etiopathogenetic aspects that underlie these diseases and identification of possible markers.

ожирениеадипоцитокиныадипонектинрезистинвисфатинФНО-αинтерлейкин

RBP4obesityadipocytokinesadiponectinRBP4interleukinTNF-alphavisfatinresistin

References1

Бутрова С.А., Ершова Е.В., Ильин А.В., Мельниченко Г.А. Адипонектин у мужчин с абдоминальным ожирением // Ожирение и метаболизм. - 2006. - Т. 2. - С. 32-36.

Бутрова С.А., Ершова Е.В., Ильин А.В. Адипоцитокины: резистин и фактор некроза опухолей-α у мужчин с абдоминальным ожирением // Ожирение и метаболизм. - 2007. - Т.4. - С. 30-33.

Косыгина А.В., Васюкова О.В. Новое в патогенезе ожирения: адипокины - гормоны жировой ткани // Проблемы эндокринологии 2009. - Т. 55. (1) - С. 44-51.

Майоров А.Ю. Состояние инсулинорезистентности в эволюции сахарного диа- бета 2 типа. Автореф. докт. дисс. Москва. С. 25-27.

AritaY. еt al. Paradoxisal decrease of an adipose-specific protein, adiponectin, inobesity. Biochem // Biophys. Res. Commun. - 1999. -№ 257. - P. 79-83.

Baratta R., Amato S., Degano C. et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies // J. Clin. Endocrinol. Metab. - 2004. - № 89. - P. 2665-71.

Bastard J.P., Jardel C., Bruckert E. et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. -2000. - № 85. - Р. 3338-42.

Berndt J., Kloting N., Kralisch S. et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans // Diabetes. - 2005. - № 54. - Р. 2911-2916.

Calabro P., Chang D.W., Willerson J.T., Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation // J. Am. Coll. Cardiol. - 2005. - № 46. - P. 1112-3.

Carey A.L., Bruce C.R., Sacchetti M. et al. Interleukin-6 and tumor necrosis factoralpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin- 6 is related to fat mass and not insulin responsiveness // Diabetologia. - 2004. - № 47. - Р. 1029-37.

Chen M., Lee Y. et al. Elevated Plasma Level of Visfatin/Pre-B Cell Colony- Enhancing Factor in Patients with Type 2 Diabetes Mellitus // J. Clin. Endocrinol. Metab. - 2006. - № 91. - Р. 295-299.

Cho Y.M., Youn B.S., Lee H. et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes // Diabetes Care. - 2006. - № 29. - Р. 2457-61.

Cnop M., Havel P.J., Utzschneider K.M. et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex // Diabetologia. - 2003. - № 46. - Р. 459-69.

Curat C.A., Bouloumie A. et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin // Diabetologia. - 2006. - № 49. - Р. 744-7.

Dahl T.B., Yndestad A., Skjelland M. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization // Circulation. - 2007. - № 115. - Р. 972-980.

Dekker J.M., Funahashi T., Nijpels G. et al. Prognostic value of adiponectin for cardiovascular disease and mortality // J. Clin. Endocrinol. Metab. - 2008. - № 93. - Р. 1489-96.

Dogru T., Sonmez A., Tasci I. et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance // Diabetes Res. Clin. Pract. - 2007. - № 76. - Р. 24-29.

Engelberts I., Stephens S., Francot G.J. et al. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids // Lancet. - 1991. - № 338. - Р. 515-6.

Febbraio M.A., Pedersen B.K. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles // FASEB J. - 2002. - № 16. - Р. 1335-47.

Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin // Science. -2005. -№ 307. - Р. 426-30.

Hivert M.F., Meigs J.B. et al. Associations of Adiponectin, Resistin, and TNF-α with Insulin Resistance // J. Clin. Endocrinol. Metab. - 2008. -№ 93(8). - P. 3165-72.

Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance // Science. - 1993. - № 259. - P. 87-91.

Hotta K., Funahashi T., Bodkin N.L. et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys // Diabetes. - 2001. - № 50. - P. 1126-33.

Isobe T., Saitoh S., Takagi S., et al. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study // Eur. J.Endocrinol. - 2005. - № 153. - P. 91-8.

Iwashima Y., Katsuya T., Ishikawa K. et al. Hypoadiponectinemia is an independent risk factor for hypertension // Hypertension. - 2004. -№ 43. - P. 1318-23.

Kistorp C., Faber J., Galatius S. et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure // Circulation. 2005. - № 112. - P. 1756-62.

Krzyzanowska K., Krugluger W., Mittermayer F. et al. Increased visfatin concentrations in women with gestational diabetes mellitus // Clin. Sci. - 2006. - № 110. - P. 605-609.

Kumada M., Kihara S., Sumitsuji S. et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. // Thromb. Vasc. Biol. - 2003. - № 23. -P. 85-9.

Lee J.W., Im J.A., Lee H.R. et al. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women // Obesity. - 2007. - № 15. - P. 2225- 32.

Levy J.R., Davenport B., Clore J.N., Stevens W. Lipid metabolism and resistin gene expression in insulin-resistant Fischer 344 rats // Am. J. Physiol. Endocrinol. Metab. - 2002. - № 282. - E626-E633.

Lindsay R.S., Funahashi T., Hanson R.L. et al. Adiponectin and development of type 2 diabetes in the Pima Indian population // Lancet. - 2002. - № 360. - P. 57-8.

Moschen A.R., Kaser A., Enrich B. et al. Visfatin, and adipocytokine with proinflammatory and immunomodulating properties // J. Immunol. 2007. - № 178. - P. 748-1758.

Oki K., Kohno N. et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance // Clin. Endocrinol. - 2007. - № 67. - P. 796-800.

Osawa H., Makino H. et al. Plasma resistin, associated with single nucleotide polymorphism- 420, is correlated with insulin resistance, lower HDL cholesterol, and high sensitivity C-reactive protein in the Japanese general population // Diabetes Care. - 2007. - № 30. - P. 1501-6.

Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue // Circulation. - 2003. - № 107. - P. 671-4.

Perseghin G., Lattuada G., De Cobelli F., et al. Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation // J. Clin. Endocrinol. Metab. - 2007. - № 92. - P. 4883-8.

Pfeiffer A., Janott J., Mohlig M. et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus // Horm. Metab. Res. - 1997. - № 29. - P. 111-4.

Pilz S., Horejsi R., Moller R. et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin // J. Clin. Endocrinol. Metab. - 2005. - № 90. - P. 4792-6.

Pilz S., Mangge H., Wellnitz B. et al. Adiponectin and mortality in patients undergoing coronary angiography // J. Clin. Endocrinol. Metab. - 2006. - № 91. - P. 277-86.

Pischon T., Bamberger C.M., Kratzsch J. et al. Association of plasma resistin levels with coronary heart disease in women // Obes. Res. - 2005. - № 13. - P. 1764-71.

Qi Q., Yu Z., Ye X. et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people // J. Clin. Endocrinol. Metab. - 2007. - № 92. - P. 4827-34.

Senolt L., Pavelka K., Housa D., Haluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis // ytokine. - 2006. - № 35. - P. 247-52.

Shetty G.K., Economides P.A., Horton E.S. et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes // Diabetes Care. - 2004. - № 27. - P.2450-7.

Shoji T., Shinohara K., Hatsuda S. et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease // Metabolism. - 2005. - № 54. - P. 330-4.

Staiger H., Tschritter O., Machann J. et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans // Obes. Res. - 2003. - № 11. - P. 368-72.

Stefan N., Vozarova B., Funahashi T. et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans // Diabetes. - 2002. - № 51. - P. 1884-8.

Stefan N., Hennige A.M., Staiger H. et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans // Diabetes Care. - 2007. - № 30. - P. 1173-8.

Steppan C.M., Bailey S.T., Bhat S. et al. The hormone resistin links obesity to diabetes // Nature. - 2001. - № 409. - P. 307-312.

Tan B.K., Randeva H.S. et al. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin // J. Clin. Endocrinol. Metab. - 2006. - № 91. - P. 5022-5028.

Tsutsumi C., Okuno M., Tannous L. et al. Retinoids and retinoid-binding protein expression in rat adipocytes // J. Biol. Chem. - 1992. - № 267. - P. 1805-10.

von Eynatten M., Hamann A., Twardella D. et al. Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease // Eur. Heart. J. - 2008. - № 9. - P. 1307-15.

Winer J.C., Zern T.L., Taksali S.E. et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome // J. Clin. Endocrinol. Metab. - 2006. - № 91. - P. 4415-23.

Xu H., Barnes G.T., Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulinresistance // J. Clin. Invest. - 2003. - № 112. - P. 1821-30.

Yang Q., Graham T.E., Mody N. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes // Nature. 2005. - № 436. - P. 356-62.

Yang W.S., Lee W.J., Funahashi T. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin // J. Clin. Endocrinol. Metab. - 2001. - № 86. - P. 3815-9.

The authors declare that there are no conflicts of interest present.